Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > conjunctivitis treatment market
Get a free sample of Conjunctivitis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Conjunctivitis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The conjunctivitis treatment industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced product based on different technologies is among a key market strategy. Some of the leading industry players including Alembic Pharmaceuticals, Novartis, Ajanta Pharma Limited, and Bausch & Lomb among others have a notable presence in the market.
Some of the eminent market participants operating in the conjunctivitis treatment industry include:
The market size of conjunctivitis treatment reached USD 4.1 billion in 2023 and is set to cross USD 6.3 billion by 2032, owing to the rising prevalence of conjunctivitis from viral outbreaks, bacterial infections, allergies, environmental influences, and increased global travel worldwide.
The anti-allergic segment is expected to reach USD 4.1 billion by 2032, due to the rising prevalence of allergic conditions, such as allergic rhinitis, allergic conjunctivitis, and asthma.
North America market was valued at USD 1.6 billion in 2023, due to growing awareness of conjunctivitis and its treatment options among healthcare professionals and the general population in the region.
AFT Pharmaceuticals, Ajanta Pharma Limited, Alembic Pharmaceuticals, Bausch & Lomb Incorporated, Cipla, Inc., JAWA Pharmaceuticals Pvt. Ltd., Novartis AG, NicOx SA, and Ocular Therapeutics, Inc., are some of the major conjunctivitis treatment companies worldwide.